Loading stock…

Kestra Medical Technologies, Ltd. (KMTS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Kestra Medical Technologies, Ltd.

KMTSMarket cap $1.61BPrice $27.1

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes wearable defibrillators that monitor heart activity and deliver life-saving shocks without surgery. Its ASSURE system directly challenges Zoll's near-monopoly, giving cardiac patients a lighter, smarter alternative to decades-old technology.

In Bastion Portfolios?

52W Return+10%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+132%10

Revenue Forecast

Rev CAGR (1y)+48%10

Rev CAGR (3y)+42%10

Rev CAGR (5y)+37%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-134%1

Net Income Margin-140%1

Free Cash Flow Margin-115%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-74%1

ROA-49%1

Earnings Stabilityna–

GEAR+VERY WEAK13

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV7.32

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-7.6%1

Dividend Yieldna–

Momentum

Short term

1 month return+6%9

3 month return-3%5

YTD return+2%5

Mid term

Price vs 52wHigh90%8

1 year return+11%6

Long term

3 year return+24%4

5 year return+24%5

Risk Shield

Price Risk

Beta1.32

Volatility62%2

Free Cash Flow

Free Cash Flow Margin-115%1

Free Cash Flow Yield-7.6%1

Quality

ROCE-54%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

KMTSKestra Medical Technologies

Revenue FY26$95M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+132%10

Revenue, next 1Y+48%10

Revenue, next 3Y, CAGR+42%10

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY29ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 132%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 42%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

Revenue grew 132%/yr over the last 3 years; forecasts see it cooling to 42%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return-3%5

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+11%6

3-year return+24%4

5-year return+24%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 11% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%).

WATCH

Average long-term results. Multi-year returns are middling (+24% over three years and +24% over five), roughly average for the market.

Returns sit at the market level over three months (-3%) and so far this year (+2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Kestra Medical Technologies, Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

KMTSKestra Medical Technologies

Revenue FY26$95M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+132%10

Revenue, next 1Y+48%10

Revenue, next 3Y, CAGR+42%10

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY29ELoss1

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 132%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 42%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

Revenue grew 132%/yr over the last 3 years; forecasts see it cooling to 42%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return-3%5

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+11%6

3-year return+24%4

5-year return+24%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 11% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%).

WATCH

Average long-term results. Multi-year returns are middling (+24% over three years and +24% over five), roughly average for the market.

Returns sit at the market level over three months (-3%) and so far this year (+2%).

WEAKNESSES

None flagged.

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up.

04Value

Are you paying a fair price for it?

Stop guessing on Kestra Medical Technologies, Ltd.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community